Arca
Skip to content
Tools
Tools

Amyloidosis

Drug research and approvals for amyloidosis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 229 studies of amyloidosis are recruiting on ClinicalTrials.gov, Health Canada has authorized 21 drug trials for it since 2013, FDA has 8 approved and 20 open orphan designations naming it, and the EU has 8 authorised medicines for it.

  • Recruiting worldwide: 229
  • Trials authorized in Canada: 21
  • FDA orphan approvals: 8
  • EU medicines: 8

Recruiting now

Newest posted first, of 229 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 3

Phase 3 6

Phase 2 9

Phase 1 or earlier 10

How its trials ended

562 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 118 whose ending is known, 47% met their primary endpoint, 4% missed it and 49% stopped early.

  • Ongoing22240%
  • Completed, result not reported16730%
  • Met its primary endpoint5510%
  • Status unknown5510%
  • Stopped: other or unclear326%
  • Stopped: enrollment or feasibility122%
  • Stopped: sponsor or business decision61%
  • Missed its primary endpoint51%
  • Stopped: lack of efficacy41%
  • Stopped: safety41%

Trials authorized in Canada

The 10 newest of 21; search them all in Canada trials
Oct 29, 2026A phase 3 multicenter, randomized, open-label study evaluating the safety and efficacy of etentamig (ABBV-383) compared to daratumumab, cyclophosphamide,…Etentamig (ABBV-383)AbbViePending
Feb 26, 2026A phase 1/2 study of linvoseltamab in patients with relapsed or refractory systemic light chain amyloidosis (LINKER-AL2)Linvoseltamab (REGN5458)RegeneronPending
Oct 31, 2025A phase 1b/2 study of AZD0120 (also known as GC012F), a chimeric antigen receptor T-cell (CAR-T) therapy targeting CD19 and B-cell maturation antigen (BCMA) in…AZD0120 (GC012F)AstraZeneca PharmaceuticalsOngoing
Oct 29, 2025Triton-pn: a phase 3, global, randomized, open-label study to evaluate the efficacy and safety of nucresiran in patients with hereditary transthyretin-mediated…Nucresiran (ALN-TTRSC04) / Vutrisiran (ALN-TTRSC02)Alnylam PharmaceuticalsOngoing
Jun 20, 2025A phase 3 global, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of nucresiran in patients with transthyretinmediated…Nucresiran (ALN-TTRSC04)Alnylam PharmaceuticalsOngoing
Oct 21, 2024A phase 3, randomized, multicenter, double-blind, placebo controlled study of acoramidis for transthyretin amyloidosis prevention in the young (act-early trial)AcoramidisEidos TherapeuticsOngoing
Feb 1, 2024A phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, tolerability, and pharmacodynamics of intrathecally…Mivelsiran (aln-app)Alnylam PharmaceuticalsOngoing
Jan 6, 2022A phase 3, open-label, multicenter, single-arm study to evaluate the efficacy and safety of acoramidis in subjects with symptomatic transthyretin amyloid…Acoramidis (AG10)Eidos TherapeuticsPending
Jan 6, 2022A phase 2, multicohort study of daratumumab-based therapies in participants with amyloid light chain (AL) amyloidosisDaratumumab (JNJ-54767414)Johnson & JohnsonOngoing
May 12, 2021A phase 3, randomized, multicenter, double-blind, placebo-controlled, efficacy and safety study of birtamimab plus standard of care vs. placebo plus standard…BirtamimabProthena Therapeutics LimitedOngoing

FDA orphan designations

Approved first, then open designations, newest first; 15 of 28
Mar 20, 2025AmvuttraTreatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular…Alnylam Pharmaceuticals, Inc.Approved
Nov 22, 2024AttrubyTreatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular…BridgeBio Pharma, Inc.Approved
Dec 21, 2023WainuaTreatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adultsIonis Pharmaceuticals, Inc.Approved
Jun 13, 2022AmvuttraTreatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adultsAlnylam Pharmaceuticals, Inc.Approved
Jan 15, 2021Darzalex FasproIn combination with bortezomib, cyclophosphamide and dexamethasone for the treatment of adult patients with newly diagnosed light chain…Janssen Research & Development, LLCApproved
May 3, 2019Vyndaqel; VyndamaxVYNDAQEL and VYNDAMAX are indicated for the treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis…FoldRx Pharmaceuticals, Inc., a subsidiary of Pfizer Inc.Approved
Oct 5, 2018Tegsedi™TEGSEDI® is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.Akcea Therapeutics, Inc.Approved
Aug 10, 2018OnpattroONPATTRO is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.Alnylam Pharmaceuticals, Inc.Approved
Jun 1, 2026Zamubafusp alfaTreatment of light chain (AL)-associated amyloidosisAttralus, Inc.Designated
Dec 2, 2025Revlucabtagene autoleucelTreatment of amyloid light chain amyloidosisNexcella, Inc.Designated
Jul 3, 2025DiflunisalTreatment of transthyretin-mediated amyloidosisPurpose Pharma International ABDesignated
Jun 5, 2025Small interfering ribonucleic acid -GalNAc conjugate…Treatment of transthyretin amyloidosis (ATTR amyloidosis)Chengdu Brilliant Pharmaceutical Co., Ltd.Designated
Mar 14, 2025CRISPR-associated protein 9-based TTR gene editing therapyTreatment of transthyretin-mediated amyloidosis-ATTRAccuredit Therapeutics US Ltd.Designated
Feb 4, 2025RNA interference (RNAi) therapeutic, that targets the…Treatment of transthyretin (TTR) -mediated amyloidosis (ATTR amyloidosis)Alnylam Pharmaceuticals, Inc.Designated
Oct 30, 2024A fusion protein of humanized immunoglobulin G1 (IgG1) with…Treatment of transthyretin-associated (ATTR) amyloidosisAttralus, Inc.Designated

Medicines authorised in the EU

Newest first
Sep 18, 2026Tafamidis AccordTafamidis · genericAccord Healthcare S.L.U.EMA ↗
Jul 17, 2025AttrogyDiflunisalPurpose Pharma International ABEMA ↗
Mar 6, 2025WainzuaEplontersenAstraZeneca ABEMA ↗
Feb 10, 2025BeyonttraAcoramidisBayer AGEMA ↗
Sep 15, 2022AmvuttraVutrisiran · orphanAlnylam Netherlands B.V.EMA ↗
Aug 27, 2018OnpattroPatisiran · orphanAlnylam Netherlands B.V.EMA ↗
Jul 6, 2018TegsediInotersen · orphanAkcea Therapeutics Ireland LimitedEMA ↗
Nov 16, 2011VyndaqelTafamidis · orphanPfizer Europe MA EEIGEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.